Michael J. Fox Foundation Earmarks up to $3 Million for Clinical Research
ďOur aim is to drive the delivery of promising therapies to patients by providing the bridge funding that enables researchers to translate results from the lab to clinical research,Ē said Deborah W. Brooks, president and chief executive officer of The Michael J. Fox Foundation for Parkinsonís Research. ďThereís currently a lack of funding to support small-to-medium sized clinical investigations, which sets up a significant roadblock to developing new treatment options for Parkinsonís.Ē
Researchers are invited to submit grant applications for clinical research that involves active patient participation and has the potential for immediate impact on the lives of people living with Parkinsonís disease. Proposals may range from studies that focus on understanding Parkinsonís disease in humans and developing scales for measuring Parkinsonís, to research supporting experimental new therapies for the treatment of Parkinsonís disease.††
ďThe Clinical Discovery Program is one expression of the Foundationís increasing focus on translational research,Ē says Ken Olden, chief scientific advisor to the Foundation. ďClinical research is critical to turning basic discoveries into meaningful advances for people with Parkinsonís disease.Ē The response from the scientific community, he adds, has been significant.
The Foundation launched the Clinical Discovery Program in 2004, awarding four grants totaling about $2 million. Projects previously funded include: a team in China† investigating the potential neuroprotective effects of green tea polyphenols; a second grant recipient testing a novel strength training technique to address dysphagia, a common condition in Parkinsonís disease that occurs when the muscles involved in swallowing weaken or do not work properly; and two teams using Positron Emission Tomography (PET) imaging to quantify changes in the brain associated with the onset of Parkinsonís disease and co-morbid conditions.
The Clinical Discovery Program is an investigator-initiated, peer-reviewed program that will provide up to $3 million in funding for clinical research projects involving active patient participation for up to three years. Those who wish to propose studies that do not involve active patient participation, but instead rely on archived biological samples, are encouraged to apply for the Foundationís 2006 Community Fast Track program. Throughout the duration of the grant, continuation of funding is dependent on the achievement of mutually agreed upon milestones. Applicants will be required to address study power, outcome and safety measures, as well as the number of patient participants required to conduct each study.
Letters of intent are due by